Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700020519

Trial Profile

Clinical Trials Insight: 700020519

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2010

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 05 Jun 2010 Nilotinib is effective regardless of BCR-ABL transcript type, according to an abstract presented at ASCO 2010.
    • 30 May 2008 Updated results for accelerated phase patients reported at ASCO 2008 (1113738)
    • 24 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top